Sam Klempner, MD, Looks at Broad Use of ctDNA in Oncology


Sam Klempner, MD, spoke about how clinicians exploring use of ctDNA in gastrointestinal cancers may inform their research with results from other tumor types.

At the 2022 International Gastric Cancer Conference, Sam Klempner, MD, of Massachusetts General Hospital, spoke to CancerNetwork® about how other areas of oncology have helped advance circulating tumor DNA (ctDNA) research for gastrointestinal cancer. He emphasizes why the ability to learn from other colleagues is so important.


We’ve taken a lot of lessons from [our colleagues treating] genitourinary, breast, and colon cancers who have generated more prospective data and have more prospective ongoing trials. This is going to be like a pan-cancer paradigm where this is a this is a shared biology. If you have breast cancer that has residual ctDNA after surgery, or esophageal cancer, those are unfavorable things. We’re going to be able to learn a lot from our colleagues, and yes, there are efforts in [the treatment of gastric and esophageal cancers] to do 2 things: one is to analyze collected blood from completed clinical trials, which will give us a lot of well-annotated and well-collected data; two, is to prospectively validate ctDNA. There are some concepts in development where patients would be assigned to a therapy based on a ctDNA status.

Related Videos
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content